Given the role of PTEN in negatively regulating the PI3K/AKT/mTOR pathway, inhibitors targeting this pathway have shown promise in preclinical studies and early-phase clinical trials for endometrial cancer [58]. The gene discussed is MTOR; the disease is endometrial cancer.